V
Venkatesh L. Hegde
Researcher at University of South Carolina
Publications - 39
Citations - 1864
Venkatesh L. Hegde is an academic researcher from University of South Carolina. The author has contributed to research in topics: Immune system & Cannabinoid receptor. The author has an hindex of 20, co-authored 34 publications receiving 1577 citations. Previous affiliations of Venkatesh L. Hegde include Central Food Technological Research Institute & Council of Scientific and Industrial Research.
Papers
More filters
Journal ArticleDOI
Cannabinoids as novel anti-inflammatory drugs
Prakash S. Nagarkatti,Rupal Pandey,Sadiye Amcaoglu Rieder,Venkatesh L. Hegde,Mitzi Nagarkatti +4 more
TL;DR: This review will focus on the potential use of cannabinoids as a new class of anti-inflammatory agents against a number of inflammatory and autoimmune diseases that are primarily triggered by activated T cells or other cellular immune components.
Journal ArticleDOI
Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor.
Narendra P. Singh,Venkatesh L. Hegde,Lorne J. Hofseth,Mitzi Nagarkatti,Prakash S. Nagarkatti +4 more
TL;DR: Data from the present study demonstrate the ability of resveratrol to trigger apoptosis in activated T cells and its potential use in the treatment of inflammatory and autoimmune diseases including, MS.
Journal ArticleDOI
Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.
Venkatesh L. Hegde,Shweta Hegde,Benjamin F. Cravatt,Lorne J. Hofseth,Mitzi Nagarkatti,Prakash S. Nagarkatti +5 more
TL;DR: The data demonstrate that targeting cannabinoid receptors using exogenous or endogenous cannabinoids and use of FAAH inhibitors may constitute novel therapeutic modalities to treat immune-mediated liver inflammation.
Journal ArticleDOI
Role of Myeloid-Derived Suppressor Cells in Amelioration of Experimental Autoimmune Hepatitis Following Activation of TRPV1 Receptors by Cannabidiol
TL;DR: This study demonstrates for the first time that M DSCs play a critical role in attenuating acute inflammation in the liver, and that agents such as CBD, which trigger MDSCs through activation of TRPV1 vanilloid receptors may constitute a novel therapeutic modality to treat inflammatory diseases.
Journal ArticleDOI
miR-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses
Udai P. Singh,Angela Murphy,Reilly T. Enos,Haidar A. Shamran,Narendra P. Singh,Honbing Guan,Venkatesh L. Hegde,Daping Fan,Robert L. Price,Dennis D. Taub,Manoj K. Mishra,Mitzi Nagarkatti,Prakash S. Nagarkatti +12 more
TL;DR: Using an acute experimental colitis model, it is found that miR‐155−/− mice, as compared to wild‐type control mice, have decreased clinical scores, a reversal of colitis‐associated pathogenesis, and reduced systemic and mucosal inflammatory cytokines.